NCT05623020
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05623020
Title A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy (MagnetisMM-6)
Acronym MagnetisMM-6
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Pfizer
Indications
Therapies
Age Groups: adult | senior
Covered Countries POL | NLD | ITA | ISR | GRC | FRA | ESP | DEU | CZE | CHE | CAN | AUS


No variant requirements are available.